BR112013002589A2 - valsatana altamente cristalina - Google Patents

valsatana altamente cristalina

Info

Publication number
BR112013002589A2
BR112013002589A2 BR112013002589A BR112013002589A BR112013002589A2 BR 112013002589 A2 BR112013002589 A2 BR 112013002589A2 BR 112013002589 A BR112013002589 A BR 112013002589A BR 112013002589 A BR112013002589 A BR 112013002589A BR 112013002589 A2 BR112013002589 A2 BR 112013002589A2
Authority
BR
Brazil
Prior art keywords
valsatana
highly crystalline
crystalline
highly
crystalline valsatana
Prior art date
Application number
BR112013002589A
Other languages
English (en)
Inventor
Thomas Hahn Björn
Andreas Rampf Florian
Burgbacher Jens
Schneeberger Ricardo
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112013002589A2 publication Critical patent/BR112013002589A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
BR112013002589A 2010-08-03 2011-08-01 valsatana altamente cristalina BR112013002589A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37028510P 2010-08-03 2010-08-03
PCT/EP2011/063254 WO2012016969A1 (en) 2010-08-03 2011-08-01 Highly crystalline valsartan

Publications (1)

Publication Number Publication Date
BR112013002589A2 true BR112013002589A2 (pt) 2019-09-24

Family

ID=44645072

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013002589A BR112013002589A2 (pt) 2010-08-03 2011-08-01 valsatana altamente cristalina

Country Status (18)

Country Link
US (1) US20130137737A1 (pt)
EP (1) EP2601180A1 (pt)
JP (1) JP2013532707A (pt)
KR (1) KR20130139863A (pt)
CN (1) CN103052630A (pt)
AR (1) AR082435A1 (pt)
AU (1) AU2011287616A1 (pt)
BR (1) BR112013002589A2 (pt)
CA (1) CA2806657A1 (pt)
CL (1) CL2013000335A1 (pt)
CO (1) CO6670580A2 (pt)
EC (1) ECSP13012459A (pt)
MA (1) MA34580B1 (pt)
MX (1) MX2013001251A (pt)
RU (1) RU2013109365A (pt)
SG (1) SG187007A1 (pt)
TW (1) TW201206428A (pt)
WO (1) WO2012016969A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103739564A (zh) * 2012-02-20 2014-04-23 中国科学院上海药物研究所 缬沙坦的多晶型及其制备方法
CN103435567B (zh) * 2013-09-09 2015-08-26 山东新华制药股份有限公司 缬沙坦的精制方法
CN105801506A (zh) * 2014-12-30 2016-07-27 天津法莫西医药科技有限公司 缬沙坦新晶型及其制备方法
JP2016150917A (ja) * 2015-02-17 2016-08-22 株式会社トクヤマ バルサルタンの結晶の製造方法
CN105777660A (zh) * 2016-03-29 2016-07-20 潍坊盛瑜药业有限公司 缬沙坦晶型e的诱导结晶工艺及应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2084801T3 (es) 1990-02-19 1996-05-16 Ciba Geigy Ag Acil compuestos.
CN1137887C (zh) * 2000-04-07 2004-02-11 常州四药制药有限公司 一种合成缬沙坦的改进方法
AU2001289672B2 (en) 2000-07-19 2005-12-08 Novartis Ag Valsartan salts
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
AU2003223637A1 (en) * 2002-04-15 2003-11-03 Dr. Reddy's Laboratories Limited Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan)
GB0222056D0 (en) * 2002-09-23 2002-10-30 Novartis Ag Process for the manufacture of organic compounds
CN1788004A (zh) * 2003-03-17 2006-06-14 特瓦制药工业有限公司 缬沙坦的多晶型
DE602004013405T2 (de) 2003-03-17 2009-05-07 Teva Pharmaceutical Industries Ltd. Polymorphe formen von valsartan
CZ298685B6 (cs) * 2003-05-15 2007-12-19 Zentiva, A.S. Zpusob výroby N-(1-oxopentyl)-N-[[2´-(1H-tetrazol-5-yl)[1,1´-bifenyl]-4-yl]methyl]-L-valinu (valsartanu)
ITMI20032267A1 (it) * 2003-11-21 2005-05-22 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procdimento per la preparzione di valsartan e suoi intermedi
US20060270723A1 (en) 2005-01-11 2006-11-30 Tamas Koltai Process for preparing amorphous valsartan
WO2007017897A2 (en) 2005-05-25 2007-02-15 Ipca Laboratories Ltd. Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amine
ITMI20051989A1 (it) * 2005-10-20 2007-04-21 Dipharma Spa Procedimerntyo per la preparazione di composti antagonisti di angiotensina ii
WO2007069271A2 (en) * 2005-10-31 2007-06-21 Alembic Limited Process for the purification of (s) -n- (l-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2' - (1h-tetraz0l-5-yl) bipheny l-4 -ylmethyl] -amine (valsartan)
CN1844110B (zh) * 2005-12-09 2010-07-14 浙江天宇药业有限公司 高光学纯度的缬沙坦的合成方法
CN101270096B (zh) * 2007-03-22 2011-08-03 浙江华海药业股份有限公司 一种合成缬沙坦的方法
CN100522953C (zh) * 2007-04-03 2009-08-05 浙江天宇药业有限公司 一种缬沙坦的新合成方法
ES2316281B1 (es) * 2007-05-14 2010-02-09 Quimica Sintetica, S.A. Procedimiento para la preparacion de valsartan.
CN101362728B (zh) * 2008-08-22 2011-07-20 北京赛科药业有限责任公司 一种缬沙坦的合成方法
CN101768128B (zh) * 2009-01-05 2012-10-10 浙江华海药业股份有限公司 一种含10%以上异构体的缬沙坦的精制方法
CN101475540B (zh) * 2009-01-22 2011-05-11 江苏德峰药业有限公司 一种缬沙坦的制备方法
CN101735164A (zh) * 2009-12-22 2010-06-16 北京赛科药业有限责任公司 缬沙坦中杂质f的研究及控制方法

Also Published As

Publication number Publication date
JP2013532707A (ja) 2013-08-19
MX2013001251A (es) 2013-03-18
EP2601180A1 (en) 2013-06-12
RU2013109365A (ru) 2014-09-10
AR082435A1 (es) 2012-12-05
CO6670580A2 (es) 2013-05-15
KR20130139863A (ko) 2013-12-23
SG187007A1 (en) 2013-02-28
US20130137737A1 (en) 2013-05-30
AU2011287616A1 (en) 2013-02-28
MA34580B1 (fr) 2013-10-02
CL2013000335A1 (es) 2013-06-14
WO2012016969A1 (en) 2012-02-09
CN103052630A (zh) 2013-04-17
ECSP13012459A (es) 2013-03-28
CA2806657A1 (en) 2012-02-09
TW201206428A (en) 2012-02-16

Similar Documents

Publication Publication Date Title
NO2019007I1 (no) Tisagenlekleucel
BR112013009935C8 (pt) compostos
BR112012028556A2 (pt) Indóis
DE102011100241A8 (de) Nitridhalbleiterbauteil
DK3225404T3 (da) Fluidpatron
BR112013003753A2 (pt) compostos
CR20130111A (es) Triazina-oxidiazoles
DE10170954T8 (de) Mikrowellendruckgarer
DE112011104226A5 (de) Käfigmutter
CO6801726A2 (es) Compuestos
DE102011117046A8 (de) Doppelkupplungswindungsgetriebe
DK2649070T3 (da) Triazolpyridinforbindelser
DE112011101226A5 (de) Linearwegmesssystem
DE112011102080A5 (de) Kupplungszentralausrücker
DK2442899T3 (da) Rotorskive
DK2539163T3 (da) Dækventil
DE102011002623A8 (de) Ventilsteuerzeitversteller
DE112011102711A5 (de) Hydrostataktor
DK2447426T3 (da) Vaske-WC
DE102010019119B8 (de) Cuttermesser
DE102010038420A8 (de) Reinigungungsvorrichtung
DK2596072T3 (da) Bor-forbindelses-suspension
DK2521486T3 (da) Palpometer
DE112010005518A5 (de) Dichtungsmanchette
CO6801789A2 (es) N-hetarilmetil pirazolilcarboxamidas

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.